The 80 Billion Dollar Question

Paul, Reid
September 2009
Pharmaceutical Representative;Sep2009, Vol. 39 Issue 9, p6
The article reports on the issue concerning the deal agreed by the Pharmaceutical Research and Manufacturers of America (PhRMA) with the U.S. Congress to receive $80 billion of funds as part of health care reform. Pharmaceutical companies raised their concern that the amount will not be enough to reduce healthcare costs in the country. In addition, the uncertainty expressed by President Barack Obama on the deal will pose challenges to the pharmaceutical industry.


Related Articles

  • Republicans Take Aim at Tauzin.  // Pharmaceutical Representative;Oct2009, Vol. 39 Issue 10, p9 

    The article reports on the conflict between Billy Tauzin, the chief executive officer (CEO) of the Pharmaceutical Research & the Manufacturers of America (PHRMA), and his Republican colleagues due to his support of the healthcare reform of President Barack Obama in the U.S. It states that House...

  • PhRMA throws ad weight behind reform as debates get heated.  // Drug Store News;9/14/2009, Vol. 31 Issue 10, p100 

    The article focuses on the advertising campaign by the Pharmaceutical Research and Manufacturers of America (PhRMA) in support of healthcare reform planned by U.S. President Barack Obama. The campaign include television, radio and print advertisements in 12 important states. It focused on...

  • House Health Care Bill Could be Problematic for Drugmakers. Young, Donna // BioWorld Today;11/2/2009, Vol. 20 Issue 211, p1 

    The article reports that some provisions in the health reform legislative package, HR 3962, in the U.S. House are likely to impact the pharmaceutical industry, warned by the Pharmaceutical Research and Manufacturers of America (PhRMA). One of the provisions offer rebates for manufacturers. On...

  • Tracking Washington.  // MondayMorning;12/5/2011, Vol. 19 Issue 44, p6 

    The article reports on the brokered deal made by American lobbyist and politician Billy Tauzin, to U.S. President Barack Obama. The deal has helped Obama to pass the healthcare reform where he left his position as chief executive officer (CEO) of PhRMA, a pharmaceutical company lobby group....

  • A Meeting Planner's Point of View. Johnson, Judy Benaroche // Pharmaceutical Executive;Sep2008 Supplement, p34 

    The article analyzes the impact of a more restrictive 2009 medical regulation of the Pharmaceutical Research and Manufacturers of America (PhRMA) on the clinical trials in the U.S. Medical practitioners fear the potential adverse effect of the revised code on the ability of pharmaceutical...

  • Pharma and Healthcare Reform, Part 2. Bush, Laura // BioPharm International;Oct2009, Vol. 22 Issue 10, p12 

    The author reflects on healthcare reform in the U.S. and its impact on the pharmaceutical industry. The author cites the bill proposed by the Senate Finance Committee led by Senator Max Baucus and the deal between the Pharmaceutical Research and Manufacturers of America (PhRMA) and the...

  • Biotech Manufacturers Face New Political Landscape. Wechsler, Jill // BioPharm International;Dec2010, Vol. 23 Issue 12, p14 

    The article reports on the issues concerning the healthcare reform plan of U.S. president Barack Obama. It states that Republicans are looking forward to cut government spending and to revise or repeal Obamacare that could negatively affect biopharmaceutical businesses. It notes that the new...

  • Obama And The Supertanker. Brownstein, Ronald // National Journal;3/20/2010, p13 

    The article focuses on the health care reform plan bill in the U.S. Congress. President Barack Obama has pushed for the health care steadily and is willing to sacrifice politically. The article relates Obama's struggle with the plan as his long-term political strategy and a measure of success of...

  • Obama's Three Stooges: SEIU, AARP and PhRMA. Babbin, Jed // Human Events;8/24/2009, Vol. 65 Issue 29, p6 

    The article looks at the role of the Service Employees International Union (SEIU), AARP and the Pharmaceutical Research and Manufacturers of America (PhRMA) in the efforts of the administration of U.S. President Barack Obama to silence the protests of Americans to the healthcare reform bill of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics